Streetbeat News

Stock Prices

HG

Hamilton Insurance Group (NYSE:HG) reported Q2 2024 GAAP EPS of $1.20, significantly beating the analyst consensus estimate of $0.75 by 60%. This represents a 242.86% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:00 pm

HCAT

Health Catalyst (NASDAQ:HCAT) reported Q2 2024 adjusted EPS of $0.12, beating the estimate of $0.08 by 50%. Sales were $75.902M, surpassing the $75.005M estimate and showing a 3.67% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:59 pm

UBER

Uber Technologies Inc. (NYSE:UBER) reported impressive second-quarter results, beating revenue and EBITDA expectations. Analysts from multiple firms have reiterated their positive ratings and raised price targets, citing strong consumer demand, operational efficiencies, and growth in Mobility and Delivery segments. Despite a slight miss in third-quarter gross bookings guidance, the overall outlook remains positive.

Portfolio Pulse from Priya Nigam

August 07, 2024 | 8:59 pm

DMAC

DiaMedica has reiterated its guidance that full enrollment for the 144 patients for the interim analysis will be completed in the first quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

GNK

Genco Shipping & Trading (NYSE:GNK) reported Q2 2024 adjusted EPS of $0.46, beating the estimate of $0.45. Sales were $107.047M, surpassing the $93.593M estimate and showing an 18.21% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

ODD

ODDITY Tech (NASDAQ:ODD) reported Q2 2024 earnings of $0.82 per share, beating the analyst estimate of $0.68 by 20.59%. Sales were $192.774 million, surpassing the $188.548 million estimate and marking a 27.40% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

ASPN

Aspen Aerogels shares are trading higher after the company reported better-than-expected Q2 revenue results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

DLB

Dolby Laboratories has provided its financial outlook for Q4 and FY24, with Q4 EPS estimated between $0.61-$0.76 vs. $0.85 expected, and revenue between $300M-$320M vs. $326.6M expected. FY24 EPS is estimated between $3.60-$3.75 vs. $3.72 expected, and revenue between $1.27B-$1.29B vs. $1.29B expected. The outlook is influenced by uncertainties such as supply chain constraints, geopolitical instability, and inflation.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

DMAC

DiaMedica Therapeutics (NASDAQ:DMAC) reported a Q2 2024 GAAP EPS of $(0.13), beating the analyst consensus estimate of $(0.16) by 18.75%.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:58 pm

MMS

Maximus (NYSE:MMS) reported Q3 2024 adjusted EPS of $1.74, beating the estimate of $1.34 by 29.85%. Sales were $1.315 billion, surpassing the $1.285 billion estimate and showing a 10.60% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:57 pm